Connect with us

Cannabis

Cannabis One Holdings Inc. Announces Strategic Rebranding to INDVR Brands Inc. and Officer and Director Updates

Newsfile

Published

on

Vancouver, British Columbia and Denver, Colorado–(Newsfile Corp. – July 31, 2020) – Cannabis One Holdings Inc. (CSE: CBIS) (“Cannabis One“, “CBIS“, or the “Company“) is pleased to announce that it has commenced the process of changing its name to “INDVR Brands Inc.”, as well as changing its ticker symbol to “IDVR”. The name change does not affect the Company’s share structure or the rights of the Company’s shareholders, and no further action is required by existing shareholders at this time.

Joshua Mann, President, commented, “The directors and executive management team have collectively decided that its current name does not properly reflect its business or its business model. The Company has over the last year and half successfully moved from a cannabis service provider to one that owns and distributes cannabis brands across the legal channels in the United States. The Company believes that rebranding will better align with this go-forward business model, its customer base and set itself up for the impending US legalization of cannabis.”

The name change is subject to CSE approval, and the Company will provide an update once it has received such approval and an effective date for the change.

The Company also wishes to announce the resignation of Jeffery Mascio from the Board of Directors and Chief Executive Officer position, effective immediately. Mr. Mascio will remain involved with the Company in an executive advisory role and is committed to the long-term success of the Company. The Company is pleased to announce that Mr. Mann has accepted the role of Interim Chief Executive Officer, while maintaining his role as President.

Further, the Company wishes to announce the resignation of Darrick Payne from the Board of Directors. The Company appreciates Dr. Payne’s contributions. Subsequent to the Company’s March 25, 2020 press release announcing the appointment of C. Regan Hauptman to the Board of Directors, due to personal circumstances, Mr. Hauptman has been unable to accept his appointment.

About Cannabis One

IF WE BRAND IT, THEY WILL COME – Cannabis One Holdings Inc. (CSE: CBIS) is focused on aggregating and optimizing popular cannabis brands throughout North America. With its unique, franchise-ready retail brand, The JointTM, and through targeted acquisition and partnership opportunities, Cannabis One intends to become the premier, globally recognized, “House of Brands”, holding a client portfolio of award-winning products with an extensive market footprint. Through the Company’s The JointTM retail concept, Cannabis One intends to leverage the consumer and brand data harvested from its retail locations to bring data-driven analytics to an emerging, branded industry. For consumers, Cannabis One desires to become the definitive source for unparalleled product selection and renowned service in an otherwise fragmented market.

Disclaimer and Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “anticipate”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “potential”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In this news release, forward-looking statements relate, among other things, to: the legalization of cannabis in the US, the completion of the corporate name change, the ability for the Company to find replacement directors and any adverse consequence thereof. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company assumes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward- looking information contained herein.

Cannabis is legal in certain States in the United States (“U.S.“), however cannabis remains illegal under U.S. federal laws. Cannabis One intends to conduct its U.S. cannabis operations in a manner consistent with the applicable State laws and compliance with regulatory and licensing requirements applicable in the applicable State. However, the readers should be aware that any change in federal guidance on enforcement actions could adversely affect Cannabis One’s ability to access private and public capital required in order to support continuing operations and its ability to operate in the U.S.

Unlike in Canada which has Federal legislation uniformly governing the cultivation, distribution, sale and possession of cannabis under the Cannabis Act (Federal), readers are cautioned that in the U.S., cannabis is largely regulated at the State level. To the knowledge of Cannabis One, there are to date a total of 33 states, plus the District of Columbia, that have legalized cannabis in some form. Notwithstanding the permissive regulatory environment of medical cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. Federal law. Strict compliance with State laws with respect to cannabis will neither absolve Cannabis One of liability under the U.S. Federal law, nor will it provide a defense to any Federal proceeding, which may be brought against Cannabis One. Any such proceedings brought against Cannabis One may materially adversely affect its operations and financial performance in the U.S. market.

Further Information: For investment inquiries, please contact Scott Koyich, Investor Relations at Scott@briscocapital.com or (403) 619-2200.

Related Links www.cannabisone.life

THIS PRESS RELEASE IS NOT FOR PUBLICATION OR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60878

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Emerald Health Therapeutics Announces Stock Option Grant

Newsfile

Published

on

Vancouver, British Columbia–(Newsfile Corp. – August 3, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) announces that it has issued an aggregate of 3,800,000 stock options to employees, consultants and directors at an exercise price of $0.21 per common share for a period of five years. All stock options will vest 25% on the date of grant and 25% on the first three anniversaries of the date of grant. Emerald has also granted an aggregate of 175,000 restricted share units to certain employees. The restricted share units will vest one year from the grant date and convert into common shares of Emerald at a fair market value of $0.21 per common share. The stock options and restricted share units have been granted pursuant to Emerald’s Omnibus Incentive Plan which has been previously approved by Emerald’s shareholders and the TSX Venture.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products, with an emphasis on life science-based innovation and production excellence. Emerald’s three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities. These assets, all in full production, include: its Metro Vancouver, BC-based greenhouse operation (78,000 square feet) capable of producing organic-certified product; Verdélite, its premium craft cannabis production indoor facility in St. Eustache, Québec (88,000 square feet); and Pure Sunfarms, its 41.3%-owned joint venture in Delta, BC, producing high quality, affordably priced products (1.1 M square feet). Its Emerald Naturals subsidiary has launched a new natural wellness product category with its non-cannabis endocannabinoid-supporting product line and is expanding distribution across Canada.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5

Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; as well as the risk factors described in Emerald’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60965

Continue Reading

Cannabis

PAOG Outlines Strategic Next Steps and Corporate Housecleaning Agenda

Newsfile

Published

on

Sandusky, Ohio–(Newsfile Corp. – August 3, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today released a letter from CEO James C. DiPrima to update shareholders on strategic next steps in addition to reviewing corporate housecleaning agenda items. The letter is included in its entirety below:

Cannot view this image? Visit: https://i2.wp.com/grassnews.net/wp-content/uploads/2020/08/paog-outlines-strategic-next-steps-and-corporate-housecleaning-agenda.jpg?w=740&ssl=1
PAOG New Logo

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6729/60946_7bc5829b742ca8b9_001full.jpg

Dear Shareholder,

The last three weeks have been busy for PAOG. Much has been accomplished – a management takeover, and two acquisitions. Expect the momentum to continue. Key contracts moving the company’s acquired cannabis biopharmaceutical technology forward are coming soon.

PAOG anticipates entering into a Contract Research Organization (CRO) agreement as a first step toward initiating an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for its RespRx Chronic Obstructive Pulmonary Disease (COPD) treatment.

Based on positive results from an informal trial of RexpRX with 25 COVID-19 patients, PAOG also plans to make a Coronavirus Treatment Acceleration Program (CTAP) application after entering into a CRO agreement.

At the same time that we are advancing our cannabis biopharmaceutical technology, we also have some general housekeeping to catch up on. PAOG is behind on its reports required to maintain “current information” status with OTC Markets. We also need to update our website and contact information. We expect to complete all promptly.

A new website is now available. The site is preliminary. Look for continuous updates. Please sign-up for our newsletter and we’ll let you know when to check back.

You can find our new website at www.paogroupinc.com.

Thank you for your interest in our mission to advance the future of medical cannabis technology.

Best Regards,
James C. DiPrima

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60946

Continue Reading

Cannabis

Spyder Cannabis Disclosure Update

Newsfile

Published

on

Vaughan, Ontario–(Newsfile Corp. – July 31, 2020) –  Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) provides an update to the filing of disclosure documents as a result of COVID-19:

Filing of Annual Disclosure Documents Due to COVID-19

In a press release dated June 25, 2020, the Company announced, among other things, that due to circumstances created by the COVID – 19 pandemic, it would not be filing its April 30, 2020 quarterly report and management discussion and analysis which was due June 29, 2020.

The Company reports that it has yet to file its April 30, 2020 quarterly report and management discussion and analysis to date.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward- looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: corporate@spydercannabis.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60930

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania